{
    "SPADE_UN_12103": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_UN_12103",
            "Peptide Name": "SP3 (De Novo Synthesis)",
            "Source": "synthetic construct",
            "Family": "Not found",
            "Gene": "Not found",
            "Sequence": "GWAKLITKAIKKI",
            "Sequence Length": 13,
            "UniProt Entry": "No entry found",
            "Protein Existence": "Synthetic form",
            "Biological Activity": [
                "Antimicrobial",
                "Antibacterial",
                "Anti-Gram-"
            ],
            "Target Organism": "[Ref.31163671] Gram-negative bacteria:Escherichia coli ATCC 25922 (MIC=25–50 µg/mL)",
            "Hemolytic Activity": "[Ref.31163671] 10% hemolysis at 50–100 μg/mL against human blood cells.",
            "Cytotoxicity": "[Ref.31163671] The cell viability of Hepa 1-6 induced by SP3 is 80.4%, 77.0%, 87.8%, 98.0%, 76.4% and 84.5% at peptide concentrations of 3.125, 6.25, 12.5, 25, 50 and 100 μg/mL.",
            "Binding Target": "Not found",
            "Linear/Cyclic": "Linear",
            "N-terminal Modification": "Free",
            "C-terminal Modification": "Amidation",
            "Stereochemistry": "L",
            "Structure Description": "Not found",
            "Formula": "C71H124N18O15",
            "Mass": 1469.86,
            "PI": 10.48,
            "Net Charge": 4,
            "Hydrophobicity": 0.25,
            "Half Life": "Mammalian:30 hourYeast:>20 hourE.coli:>10 hour",
            "Function": "Antibacterial activity against Gram-negative bacteria.",
            "Literature": [
                {
                    "Title": "De Novo Design and In Vitro Testing of Antimicrobial Peptides against Gram-Negative Bacteria.",
                    "Pubmed ID": "31163671",
                    "Reference": "Pharmaceuticals (Basel). 2019 Jun 3;12(2). pii E82. doi 10.3390/ph12020082.",
                    "Author": "Boris Vishnepolsky, George Zaalishvili, Margarita Karapetian, Tornike Nasrashvili, Nato Kuljanishvili, Andrei Gabrielian, Alex Rosenthal, Darrell E. Hurt, Michael Tartakovsky, Maya Grigolava and Malak Pirtskhalava",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=31163671"
                },
                {
                    "Title": "De novo Design and In Vitro Testing of Antimicrobial Peptides against Gram-negative Bacteria",
                    "Pubmed ID": "",
                    "Author": "Vishnepolsky B, Zaalishvili G, Karapetian M, nasrashvili T, Kuljanishvili n, Gabrielian A, Rosenthal"
                }
            ],
            "Frequent Amino Acids": "KIA",
            "Absent Amino Acids": "CDEFHMNOPQRSUVY",
            "Basic Residues": 4,
            "Acidic Residues": 0,
            "Hydrophobic Residues": 7,
            "Polar Residues": 7,
            "Positive Residues": 4,
            "Negative Residues": 0,
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_UN_08830",
                    "Similarity": 1.0,
                    "Sequence": "KKIIPLITLFVVTLVG"
                },
                {
                    "SPADE_ID": "SPADE_N_11879",
                    "Similarity": 1.0,
                    "Sequence": "IKKISTAKI"
                },
                {
                    "SPADE_ID": "SPADE_N_11883",
                    "Similarity": 1.0,
                    "Sequence": "IKKISTKKI"
                }
            ]
        }
    }
}